US2021139843A1PendingUtilityA1
Systems and methods for growing cells in vitro
Assignee: YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTDPriority: Jul 11, 2016Filed: Jan 19, 2021Published: May 13, 2021
Est. expiryJul 11, 2036(~9.9 yrs left)· nominal 20-yr term from priority
Inventors:Yaakov Nahmias
C12M 29/18C12N 5/0062C12N 2506/1307C12M 29/10C12M 29/04C12M 21/00A01N 1/00
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A system for growing cells comprising a bioreactor chamber for growing the cells, a delivery system delivering a perfusion solution to the bioreactor chamber for perfusion of the perfusion solution through the cells, a dialysis system having a dialyzer, a dialysate for performing a dialysis and a filter for reducing ammonia content in said dialysate, and a controller that circulates the perfusion solution through the dialyzer and the dialysate through the filter.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of generating a composition comprising a cultured fat and a plant-derived protein matrix, the method comprising:
culturing an adipocyte cell in vitro to obtain the cultured fat; and adding the plant-derived protein matrix to the cultured fat,
thereby generating the composition comprising cultured fat and a plant-derived protein matrix.
2 . The method according to claim 1 , wherein the adipocyte cell is generated from a fibroblast.
3 . The method of claim 2 , wherein the fibroblast is a spontaneously immortalized fibroblast.
4 . The method according to claim 1 , wherein the culturing of the adipocyte cell occurs in a suspension culture.
5 . The method of according to claim 1 , wherein the culturing of the adipocyte cell is performed on a plant-derived protein matrix, thereby generating the cultured fat on the plant-derived protein matrix.
6 . The method according to claim 3 , further comprising generating the adipocyte cell from a spontaneously immortalized fibroblast by culturing a spontaneously immortalized fibroblast in a serum-free medium comprising oleic acid and a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist or activator.
7 . The method of claim 6 , wherein the PPAR-gamma agonist or activator is rosiglitazone.
8 . The method of claim 6 , wherein the spontaneously immortalized fibroblast is a chicken embryonic fibroblast.
9 . The method according to claim 1 , wherein the plant-derived protein matrix comprises at least one plant-derived protein from the legume (Fabaceae) family, the cereal family, or the pseudocereal family.
10 . The method according to claim 9 , wherein the at least one plant-derived protein is from the legume (Fabaceae) family and is selected from the group consisting of alfalfa, pea, bean, lentil, carob, soybean, and peanut proteins and combinations thereof.
11 . The method according to claim 10 , wherein the at least one plant-derived protein is a soy protein or a pea protein.
12 . The method according to claim 9 , wherein the at least one plant-derived protein is from the cereal family and is selected from the group consisting of maize, rice, wheat, barely, sorghum, millet, oats, rye, tritcale, and fonio proteins and combinations thereof.
13 . The method according to claim 9 , wherein the at least one plant-derived protein is from the pseudocereal family and is selected from the group consisting of buckwheat, quinoa , and chia proteins and combinations thereof.
14 . The method according to claim 1 , wherein the plant-derived protein matrix comprises a soy protein or a pea protein.
15 . A composition produced according to the method of claim 1 , wherein the composition is a meat substitute product.
16 . A meat substitute product comprising:
a cultured fat obtained from culturing, in-vitro, an adipocyte cell; and a plant-derived protein matrix.
17 . The meat substitute product of claim 16 , wherein the adipocyte cell is generated from a fibroblast.
18 . The meat substitute product of claim 17 , wherein the fibroblast is a spontaneously immortalized fibroblast.
19 . The meat substitute product of claim 16 , wherein the adipocyte cell is cultured in a suspension medium.
20 . The meat substitute product of claim 19 , wherein the suspension medium is a serum-free medium comprising oleic acid and a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist or activator.
21 . The meat substitute product of claim 16 , wherein the plant-derived protein matrix comprises at least one plant-derived protein from the legume (Fabaceae) family, the cereal family, or the pseudocereal family.
22 . The meat substitute product of claim 21 , wherein the at least one plant-derived protein is from the legume (Fabaceae) family and is selected from the group consisting of alfalfa, pea, bean, lentils, carob, soybean, and peanut proteins and combinations thereof.
23 . The meat substitute product of claim 22 , wherein the at least one plant-derived protein is a soy protein or a pea protein.
24 . The meat substitute product of claim 21 , wherein the at least one plant-derived protein is from cereal family and is selected from the group consisting of maize, rice, wheat, barely, sorghum, millet, oats, rye, tritcale, and fonio proteins and combinations thereof.
25 . The meat substitute product of claim 22 , wherein the at least one plant-derived protein is from the pseudocereal family and is selected from the group consisting of buckwheat, quinoa, and chia proteins and combinations thereof.
26 . The meat substitute product of claim 16 , wherein the plant-derived protein matrix comprises a soy protein or a pea protein.
27 . The meat substitute product of claim 16 , wherein the spontaneously immortalized fibroblast is a chicken embryonic fibroblast.
28 . A composition for the in-vitro production of cultured fat, the composition comprising
an adipocyte cell; and a serum-free medium, wherein the adipocyte cell generates the cultured fat.
29 . The composition of claim 28 , wherein the adipocyte cell is generated from a spontaneously immortalized fibroblast.
30 . The composition of claim 29 , wherein the serum free medium comprises oleic acid and PPAR-gamma agonist or activator.Join the waitlist — get patent alerts
Track US2021139843A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.